Finally, we used 1-Azakenpaullone (a GSK-3β inhibitor) to demonstrate the necessity of GSK-3β activity in the regulation by BYSL of GBM cell migration, invasion, and EMT. The gene discussed is BYSL; the disease is glioblastoma.